

Eva Galvan, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Eva Galvan, M.D.
Dr. Eva Galvan is a radiation oncologist who specializes in treating tumors of the central nervous system (brain and spine) and pediatric cancers. She uses contemporary radiation techniques such as intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), and surface imaging (for patient positioning on the treatment machine) to improve treatment outcomes and minimize long-term side effects of radiation therapy. In addition to her clinical responsibilities, Dr. Galvan has participated extensively in both clinical and basic, translational research and has presented her findings at multiple national conferences. Her current translational lab research is related to improving outcomes for patients with glioblastoma multiforme by optimizing a combination of immunotherapy, radiation therapy and novel anti-cancer drugs. She is involved in resident education and currently serves as the course director for radiation biology for radiation oncology residents.
Gender
- Female
Languages Spoken
- English
- Spanish
- French
-
Credentials
Credentials
Positions
- Assistant Professor, Radiation Oncology, University of Texas Health Science Center San Antonio
Education
Undergraduate: Yale University, New Haven, CT
Medical School: University of Texas Health Science Center San Antonio, San Antonio, TX
Internship: UT Health San Antonio, San Antonio, TX
Residency: UT Health San Antonio, San Antonio, TX
- Locations & Contact
-
Research & Publications
Research & Publications
No Research & Publications
-
Clinical Trials
Clinical Trials
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT03799523
Principal Investigator
Eva Galvan M.D.
Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy
The first goal of this project is to validate the superiority of semi-permanent marks used in conjunction with specialized light-based surface imaging (SIGRT) in an effort to phase out the use of permanent tattoos for the investigator's patients. The secondary goal of this project is to validate the superiority of specialized light-based surface imaging for daily radiation set-up compared to…
ClinicalTrials.gov Identifier
NCT06500455
Principal Investigator
Eva Galvan M.D.
NRG-BN013: PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED SRS (FSRS) FOR INTACT BRAIN METASTASES
NRG-BN013 is an unblinded, randomized phase III trial to determine if the time to local failure is significantlylonger with FSRS compared to SRS in patients with intact brain metastasis.